Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice. 1994

Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
Department of Anestliesioloyy, Osaka Medical College, TakatsukiJapan Department of Cell Biology, Osaka BioScience Institute, SuitaJapan.

We recently reported that intrathecal (i.t) administration of prostaglandin (PG) F2 alpha to conscious mice induced allodynia that was elicited by non-noxious brushing of the flanks. In the presents study, we demonstrate that i.t. administration of PGD2 and PGE2 to conscious mice also results in allodynia. Dose dependency of PGD2 for allodynia showed a skewed bell-shaped pattern (0.1 ng-2.5 micrograms/mouse), and the maximal allodynic effect was observed with 1.0 microgram at 15 min after intrathecal injection. PGD2-induced allodynia showed a time course and dose dependency similar to that induced by PGF2 alpha, but with lower scores. On the other hand, dose dependency of PGE2 for allodynia showed a bell-shaped pattern over a wide range of dosage from 10 fg to 2.0 micrograms/mouse. The maximal allodynic effect was observed with 0.01-0.1 microgram at 5 min after i.t. injection, and the response gradually decreased over the experimental period of 50 min. Intrathecally administered strychnine and the GABAA antagonist bicuculline also induced allodynia in conscious mice. The time courses of allodynia evoked by strychnine and bicuculline coincided with those by PGE2 and PGF2 alpha, respectively. PGE2-induced allodynia was dose-dependently relieved by the strychnine-sensitive glycine receptor agonist taurine, the NMDA receptor antagonist ketamine, and a high dose of the alpha 2-adrenergic agonist clonidine, but not by the GABAA agonist muscimol or by the GABAB agonist baclofen. In contrast, PGF2-induced allodynia was dramatically inhibited by clonidine and baclofen, but not by taurine, ketamine or muscimol.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D005971 Glutamates Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. Glutamic Acid Derivatives,Glutamic Acids,Glutaminic Acids
D006930 Hyperalgesia An increased sensation of pain or discomfort produced by minimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve. Hyperalgesia, Tactile,Hyperalgesia, Thermal,Hyperalgia,Hyperalgia, Mechanical,Hyperalgia, Primary,Hyperalgia, Secondary,Allodynia,Allodynia, Mechanical,Allodynia, Tactile,Allodynia, Thermal,Hyperalgesia, Mechanical,Hyperalgesia, Primary,Hyperalgesia, Secondary,Hyperalgesic Sensations,Mechanical Allodynia,Mechanical Hyperalgesia,Tactile Allodynia,Thermal Allodynia,Allodynias,Hyperalgesias,Hyperalgesias, Thermal,Hyperalgesic Sensation,Mechanical Hyperalgia,Mechanical Hyperalgias,Primary Hyperalgia,Primary Hyperalgias,Secondary Hyperalgia,Secondary Hyperalgias,Sensation, Hyperalgesic,Sensations, Hyperalgesic,Thermal Hyperalgesia
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001640 Bicuculline An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors. 6-(5,6,7,8-Tetrahydro-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)furo(3,4-e)1,3-benzodioxol-8(6H)one
D013331 Strychnine An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison. Strychnine Nitrate,Nitrate, Strychnine
D015230 Prostaglandin D2 The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. 11-Dehydroprostaglandin F2alpha,PGD2,11-Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2alpha,D2, Prostaglandin,F2 alpha, 11-Dehydroprostaglandin,F2alpha, 11-Dehydroprostaglandin,alpha, 11-Dehydroprostaglandin F2

Related Publications

Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
May 1995, Pain,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
September 1996, The Journal of pharmacology and experimental therapeutics,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
February 1990, Brain research,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
May 1995, British journal of pharmacology,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
December 1995, Neuroscience letters,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
January 2009, International review of neurobiology,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
October 1997, British journal of pharmacology,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
June 1999, The European journal of neuroscience,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
March 1986, European journal of pharmacology,
Toshiaki Minami, and Rumiko Uda, and Shigeko Horiguchi, and Sciji Ito, and Masayoshi Hyodo, and Osamu Hayaishi
October 2005, Neuropeptides,
Copied contents to your clipboard!